Portfolio

Synteni

Synteni pioneered the use of DNA microarrays for the genomic revolution. Starting with an academic research project, Shalon Ventures developed Synteni into one of the leading genomic players and service providers in four years. Two years after its founding, Shalon Ventures obtained follow-on funding for Synteni from Kleiner Perkins Caufield and Byers (www.kpcb.com), with Brook Byers joining the Synteni Board of Directors. Synteni was acquired in 1999 by Incyte (NASDAQ: INCY).